SEC Form 4 · accession 0001209191-15-075174

Arcadia Biosciences, Inc. · RKDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Oct 9, 2015

Accepted (ET)

Oct 13, 2015 · 12:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001469443

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 9, 2015	M	15,782	$0.44	A	144,775	D
Common Stock^F2	Oct 9, 2015	S	5,145	$3.0066	D	139,630	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$0.44	Oct 9, 2015	M	15,782	D	—	Dec 31, 2015	Common Stock	15,782	0	D

F1The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan (the "Plan"), adopted by the Reporting Person on June 14, 2015. Pursuant to the Plan and in compliance with the Issuer's IPO Lock-up Agreements with Credit Suisse Securities (USA) ("CSSU"), the Reporting Person paid the exercise price and CSSU sold shares only to satisfy the tax liability and costs. The balance of the shares will be held until the expiration of the IPO Lock-up Agreements.
F2This transaction was executed in multiple trades at prices ranging from $2.97 to $3.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3The option is fully exercisable as of the date hereof.